VotedBy VotedBy ⌕
Election Day · Tue, Nov 3See how your members of Congress voted →

S. 1813 · 117th Congress

Accelerating Access to Critical Therapies for ALS Act

Key: what the circles and colors mean

Each circle is a bill. The ring fills as it moves through Congress:

IntroducedPassed one chamberPassed both chambersBecame law (gold)Resolution agreed to (full, dark)Failed or vetoed (gray)

Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.

Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.

Never voted on. It didn't reach a floor vote before the 117th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.

CCD CoonsSponsor
63 cosponsors · 39 D, 22 R, 2 I
LMR Murkowski JBR Boozman AKI King SCR Capito JSD Shaheen MBD Bennet DFD Feinstein MKD Kelly PLD Leahy JMD Manchin APD Padilla KSD Sinema JTD Tester JHR Hoeven RMR Marshall RBD Blumenthal BCD Casey KGD Gillibrand JIR Inhofe CMD Murphy JRD Rosen BSD Schatz JMR Moran EMD Markey SCR Collins JTR Thune EWD Warren RDD Durbin AKD Klobuchar DSR Sullivan DSD Stabenow CVD Van Hollen CCD Cortez Masto GPD Peters TSD Smith MHD Hassan MHD Hirono SBD Brown RBR Blunt BLD Luján TBD Baldwin SWD Whitehouse TCD Carper BCR Cassidy JBR Barrasso CLR Lummis JMD Merkley TDD Duckworth DFR Fischer MHD Heinrich MRR Rounds BSI Sanders RBR Burr SDR Daines MBR Braun JKR Kennedy JOD Ossoff BHR Hagerty MBR Blackburn JRD Reed CBD Booker BMD Menendez MWD Warner

1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.

This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions.

What it does: CRS summary · Introduced in Senate · May 25, 2021

Accelerating Access to Critical Therapies for ALS Act

This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions.

The Department of Health and Human Services (HHS) shall award grants to eligible entities to facilitate patients' access to investigational drugs that diagnose or treat ALS. The Food and Drug Administration (FDA) shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other severely debilitating neurodegenerative diseases.

HHS shall also establish the Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the FDA, and at least one eligible entity (generally, an institution of higher education or a nonprofit organization). The partnership shall support the development and regulatory review of drugs that address ALS and other rare neurodegenerative diseases.

The FDA shall publish on its website a five-year action plan for fostering the development of drugs that improve or extend the lives of people living with rare neurodegenerative diseases.

Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov

About this bill and sources

Official title: Accelerating Access to Critical Therapies for ALS Act

Latest action (May 25, 2021): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Policy area: Health · Origin: Senate · Introduced: May 25, 2021

Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)

No recorded floor vote found.